João L. de Quevedo, MD, Ph.D., obtained his Medical Degree and completed residency training in Psychiatry, a fellowship in Psychopharmacology, and a Ph.D. in Biological Sciences (Biochemistry), all from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil. He is the John S. Dunn Distinguished Professor at the Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston). He also serves as Professor, Vice-Chair for Faculty Development and Outreach, Executive Director of the Center for Interventional Psychiatry, Chief of the Division of Interventional Psychiatry, Director of the Treatment-Resistant Depression Program, and Program Director of the Interventional Psychiatry Fellowship. Dr. Joao L. de Quevedo is an Associate Editor for Molecular Psychiatry, a Springer Nature journal.Research profiles:ResearcherID: E-5491-2013Scopus Author ID: 56971689500https://orcid.org/0000-0003-3114-6611Dr. Patricio Riva-Posse, MD is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. After completing his training in Neurology and in Psychiatry, he has focused his clinical and research work in the field of treatment resistant mood disorders. He is the Director of the Treatment Resistant Depression Clinic, and Director of Neuromodulation Services. He conducts research in invasive and non-invasive neuromodulation as well as novel pharmacological approaches. He is an investigator in NIH-funded project studying subcallosal cingulate deep brain stimulation. Born in Argentina, he earned his Medical Doctor degree from the Universidad de Buenos Aires. Dr. William V. Bobo, M.D., M.P.H., is Professor of Psychiatry at the Mayo Clinic Alix School of Medicine and Chair, Department of Psychiatry & Psychology at Mayo Florida, where he also serves as the Medical Director for Leadership Development. His clinical and research interests are focused on the treatment of patients with refractory mood disorders and on examining and predicting the clinical effects — both beneficial and harmful--of medications used to treat people with severe mood disorders. He lives with his wife in Jacksonville, Florida.

*4 stars* "...presents a comprehensive, extensive review of the current understanding of depression, its epidemiology, presentation, predictors, socioeconomic burden, neurobiology, and effectiveness of pharmacotherapy and nonpharmacological and psychotherapeutic interventions. This book extensively reviews the current understanding of treatment-resistant depression (TRD), covering a wide variety of topics including disease burden, presentation, and course…. [A]ppropriate for a broad audience,… covers a broad range of topics across 500-plus pages and 40 chapters,… a resource that should be on the shelves of those managing this complicated and challenging population.” --©Doody’s Review Service, 2023, Michael Easton, MD (Rush University Medical Center)

• 1. Defining treatment-resistant depression, difficult-to-treat depression, and staging treatment intensity2. Clinical and epidemiological predictors of treatment-resistant depression3. The economic burden of treatment-resistant depression: Cost-of-illness perspective4. The neurobiology of treatmentresistant depression5. Modeling treatment-resistant depression in the preclinical setting6. Treatment algorithms for treatment-resistant depression7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence8. Tricyclic antidepressants for treatment-resistant depression9. Monoamine oxidase inhibitors for treatment-resistant depression10. Switching antidepressants in patients with treatment-resistant depression11. Adjunctive strategies for treatment-resistant depression12. Combining antidepressants to address treatment-resistant depression13. Ketamine/esketamine for treatment-resistant depression14. Psychedelic agents for treatmentresistant depression15. Inflammation and treatment resistance: Mechanisms and treatment implications16. Opioid agents for treatmentresistant depression17. Transcranial magnetic stimulation for treatment-resistant depression18. tDCS for treatment-resistant depression19. ECT for treatment-resistant depression20. MST for treatment-resistant depression21. VNS for treatment-resistant depression22. Deep brain stimulation for treatment-resistant depression23. Other neurosurgical interventions for treatment-resistant depression24. Treatment-resistant psychotic depression25. Evidence-based psychotherapy for treatment-resistant depression26. Treatment-resistant bipolar depression27. Treatment-resistant depression in child and adolescents28. Treatment-resistant depression in geriatrics29. Identification and management of anxious depression in patients with treatment-resistant depression30. Managing treatment-resistant depression with comorbid personality disorders31. Managing treatment-resistant depression with comorbid substance use disorders32. Managing treatment-resistant depression in the setting of chronic pain33. Inhaled gases for treatmentresistant major depression34. Drugs under investigation for treatment-resistant depression35. Chronotherapeutics for treatmentresistant depression36. Managing treatment resistant depression in primary care settings37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause38. Lifestyle interventions for treatment-resistant depression39. Managing the risk of suicide in people with treatment-resistant depression40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression